There’s a procurement problem in dermatology that nobody talks about at conferences. It isn’t the cost of lasers or the wait time for biologic approvals. It’s the fact that most practices are still buying their everyday clinical supplies the same way they did fifteen years ago, through a single distributor, on a contract they haven’t renegotiated since their last lease renewal.
That operational model made perfect sense in an era of stable supply chains and predictable product availability. However, the dermatology market of 2026 looks fundamentally different than it did even three years ago. Today, practices are caught in a brutal squeeze: inflation-adjusted operating costs have surged by roughly 39 percent, while Medicare physician reimbursement has plummeted 33 percent in real terms since 2001. Compounding this severe financial pressure is a fractured supply chain. The critical products dermatology practices rely on daily—from prescription topicals to injectable aesthetics and wound care dressings—are now caught in the exact same shortages and tariff battles suffocating the rest of the healthcare industry.
In response to these mounting pressures, a growing number of practices—ranging from fierce independents to large PE-backed groups—are entirely rethinking their approach to supply chain management. This shift is not a dramatic, risky overhaul; rather, it is a deeply practical adaptation to a broken system. As the landscape continues to evolve, it is worth examining their strategies and asking: should your practice be making this move, too?
Table of Contents
Most dermatology practices rely on one primary distributor, usually locked into a GPO contract. On the surface, it offers seamless convenience: one account, one rep, one ordering system.
But it also creates a massive single point of failure. When that primary distributor drops the ball—due to manufacturer backorders, strict allocation limits, or tariff-driven price spikes—the practice has zero safety net. Instead of treating patients, your staff spends their entire morning desperately dialing phones.
This isn’t hypothetical. The AAD’s practice management resources have consistently highlighted supply chain awareness as a growing operational concern for dermatologists. When Baxter’s IV fluid production dropped 60 percent after Hurricane Helene in 2024, it wasn’t just hospitals that felt the impact. Outpatient practices running infusions for biologics, hydration therapy, and aesthetic treatments scrambled for alternatives too. Practices that had diversified their sourcing before the crisis didn’t skip a beat. The ones that hadn’t were rescheduling patients.
Direct-source procurement doesn’t mean cutting out distributors entirely. It means building purchasing relationships with multiple qualified suppliers so that your practice isn’t captive to a single source for any critical product category. For dermatology, those categories typically include prescription topicals and oral medications, injectable aesthetics and biologics, wound care and post-procedure dressings, exam gloves, and sterile supplies for biopsy and excision trays.
The practical benefit is straightforward. When your primary distributor puts a product on allocation or raises the price mid-contract, you have a second source already credentialed and active. Your allocation from that second supplier is based on your purchasing history with them, not your urgency on the day the shortage hits. Practices that wait until a crisis to find a backup vendor discover that the backup vendor’s allocation queue is already full.
Direct sourcing also introduces a compliance dimension that practices can’t afford to ignore. Under the Drug Supply Chain Security Act, every supplier of prescription products must provide electronic, package-level traceability documentation. That includes the topical retinoids, injectable biologics, and controlled substances that dermatology practices dispense or administer daily. Fines for noncompliance run up to $500,000 per violation. Any supplier your practice purchases from needs to be DSCSA compliant with full serialized traceability, not just competitive on price.
Dermatology sits at a unique intersection of pressures that make supply procurement more strategic than it’s ever been. PE consolidation is accelerating, with platform practices commanding 12 to 15 times EBITDA compared to 4 to 9 times for independents. Consolidated groups negotiate dermatology supplies across dozens of locations with centralized procurement teams. Independent practices that don’t build similar sourcing resilience risk getting squeezed on both the revenue side, through declining reimbursement, and the cost side, through rising supply expenses with no leverage to control them.
At the same time, the aesthetic side of dermatology is growing fast. Med spas, cosmetic clinics, and practices offering injectables and laser treatments need reliable access to high-margin products that are frequently subject to allocation and supply constraints. A practice that can’t get Botox or hyaluronic fillers on time doesn’t just lose revenue for a day. It loses the patient who rebooks somewhere else.
The move to direct-source procurement doesn’t require overhauling your entire purchasing operation overnight. Start with a simple audit: How many suppliers does your practice currently purchase from? For your top ten most-used products, how many of those come from a single source? If that source went on allocation tomorrow, how long would it take to find an alternative?
If the answers make you uncomfortable, that’s the signal. The practices that are building sourcing resilience now, before the next shortage, tariff increase, or manufacturer recall, are the ones that won’t be making panicked phone calls when it happens. And in a market where margins are already under pressure from every direction, the ability to keep your supply shelves full while your competitors scramble isn’t just an operational advantage. It’s a competitive one.
About the Author
Kevin Claussen is the co-founder/CMO at USA MedPremium, a Florida-based medical supply company serving dermatology practices, hospitals, aesthetic clinics, med spas, infusion centers, and specialty pharmacies nationwide. With a catalog of over 500,000 products including prescription topicals, injectable medications, wound care supplies, and sterile procedure trays, USA MedPremium provides DSCSA-compliant, multi-manufacturer sourcing for healthcare facilities seeking supply chain resilience.
Leave a Reply